Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity by Wainwright, EN & Scaffidi, P
Trends
Epigenetic regulators are one of the
most commonly mutated classes of
genes in cancer. During cancer initia-
tion, mutated epigenetic regulators
lead to oncogenic cellular reprogram-
ming and promote the acquisition of
uncontrolled self-renewal. The emer-
gence of CSCs requires elaborate
reorganization of the epigenome.
During cancer growth, epigenetic
mechanisms integrate the effect of
cell-intrinsic (i.e., subclonal mutations)
and cell-extrinsic (i.e., signaling from
the microenvironment) changes and
establish intratumoral heterogeneity,
either promoting or inhibiting the
CSC state.
‘Loose’ epigenetic constraints in can-
cer cells enhance cellular plasticity and
allow reversible transitions between
different phenotypic states. Enhanced
cellular plasticity favors cancer cell
adaptability and resistance to therapy.
Modulation of epigenetic processes
allows targeting of the most down-
stream determinants of the CSC state.
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Epigenetic mechanisms have emerged as key players in cancer development
which affect cellular states at multiple stages of the disease. During carcino-
genesis, alterations in chromatin and DNA methylation resulting from genetic
lesions unleash cellular plasticity and favor oncogenic cellular reprogramming.
At later stages, during cancer growth and progression, additional epigenetic
changes triggered by interaction with the microenvironment modulate cancer
cell phenotypes and properties, and shape tumor architecture. We review here
recent advances highlighting the interplay between epigenetics, genetics, and
cell-to-cell signaling in cancer, with particular emphasis on mechanisms rele-
vant for cancer stem cell formation (CSC) and function.
Epigenetic Changes in Cancer Initiation and Maintenance
The molecular makeup of a cancer is the result of multiple changes occurring progressively
during its lifetime. Early in the disease, alterations in key genes disrupt normal cell function and
endow cells with the ability to initiate a tumor or a hematological malignancy. Subsequently, as
a cancer grows, additional changes superimpose onto the initiating events and affect the
biological properties of cells, either enhancing or inhibiting their malignant properties. As a result
of this constant modulation of cell function, tumors comprise a remarkable collection of distinct
cellular phenotypes which differentially contribute to disease progression.
Intratumoral functional heterogeneity (see Glossary) has, in part, a genetic basis.
Sequencing studies have identiﬁed the presence of both clonal mutations, which represent
early initiating events, and subclonal mutations that occur at later stages of cancer growth and
only affect subsets of cancer cells [1]. While in some cancers distinct subclones coexist and
collectively drive tumor growth [2], in others subclonal mutations confer a selective advantage
and contribute to deﬁning which cells will sustain the disease. Subclonal mutations can also be
deleterious and counteract the effects of initiating mutations, resulting in loss of malignant
properties in some cells [1].
Similarly, epigenetic mechanisms involving DNA methylation and chromatin play a diverse
role in cancer by promoting, sustaining, enhancing, or inhibiting malignant phenotypes at
various stages of the disease. Research over the past decade has revealed that both cell-
intrinsic (i.e., mutations) and cell-extrinsic (i.e., environmental cues) mechanisms modulate the
epigenome of cancer cells, and their combined effect determines which cells preserve the self-
renewal capacity acquired during tumorigenesis. These cells, referred to as cancer stem cells
(CSCs) or leukemic stem cells (LSCs), are those responsible for driving long-term cancer372 Trends in Cancer, May 2017, Vol. 3, No. 5 http://dx.doi.org/10.1016/j.trecan.2017.04.004
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Glossary
Cancer stem cells (CSCs): cancer
cells endowed with unlimited self-
renewal potential that are responsible
for tumor maintenance. Operative
deﬁnition: cells that can propagate
the disease when transplanted into
immunocompromised mice,
recapitulating the cellular
heterogeneity observed in the
primary tumor.
Cellular Plasticity: the ability of
cells to transition between different
phenotypic states.
Epigenetic mechanisms: molecular
processes affecting cell behavior via
changes in gene expression that do
not involve genetic alterations.
Epigenetic mechanisms are primarily
mediated by changes in chromatin
structure and DNA methylation




heterogeneity: the presence of two
or more subpopulations of cancer
cells with distinct biological
properties within the same tumor.growth and disease progression [3]. CSCs/LSCs evolve over time as a consequence of genetic
heterogeneity, that generates self-renewing subclones with diverse ﬁtness, and environmental
changes that modulate their phenotype [3]. In this review we discuss mechanisms and
implications of the emerging role of epigenetics in the formation and function of CSCs/LSCs,
focusing on how changes in DNA methylation and chromatin affect cellular plasticity at
various stages of the disease.
Epigenetic Mechanisms Promoting the Acquisition of Uncontrolled Self-
Renewal and CSC Formation
The recent identiﬁcation of driver mutations affecting a wide range of epigenetic regulators in
hierarchically organized cancers provides direct evidence for the importance of epigenetic
dysregulation in the formation of CSCs. These mutations are typically clonal and promote the
acquisition of uncontrolled self-renewal.
Chromatin-Related Drivers Inducing CSC Formation
Leukemias represent a paradigm of hierarchical cancers maintained by LSCs. Numerous
studies have identiﬁed mutated epigenetic regulators that favor the acquisition of uncontrolled
self-renewal ability and initiate the disease. A prominent example is offered by mixed lineage
leukemia (MLL)-associated leukemia, which is characterized by chromosomal rearrangements
involving the KMT2A/MLL gene. KMT2A/MLL encodes a histone methyltransferase that
orchestrates several essential cellular processes through modiﬁcation of chromatin, mainly
regulating accessibility to enhancer regions [4]. Oncogenic MLL fusion proteins created by
translocations induce LSC formation in acute myeloid leukemia (AML) and acute lymphoblastic
leukemia (ALL) [4,5]. Importantly, MLL fusion proteins can initiate the oncogenic process both in
hematopoietic stem cells and in short-lived progenitors, suggesting that they are able to
reprogram committed cells and actively confer de novo self-renewal capacity [6–8]. Notably,
efﬁcient leukemic reprogramming of myeloid progenitors by MLL chimeras requires the action
of a MLL antagonist, the Polycomb group (PcG) protein BMI1, to ensure repression of tumor-
suppressor genes that would otherwise counteract the effect of the oncogenic fusions [9,10].
Furthermore, the observations that different cell types respond differently to the presence of
MLL fusion proteins [11], and that diverse types of leukemia can be induced by the same
oncoprotein, suggest that the epigenetic landscape of the cancer cell-of-origin may inﬂuence
the effect of MLL chimeric proteins [12,13]. Recurrent mutations in MLL proteins have also been
identiﬁed in a variety of solid tumors [14–17], pointing to MLL proteins as general cancer drivers.
In addition to histone modiﬁers, mutated structural proteins regulating the higher-order struc-
ture of chromatin, such as cohesins, have been shown to enforce stem cell transcriptional
programs and have been implicated in the emergence of LSCs [18]. Moreover, inactivating
mutations disrupting the function of chromatin-remodeling complexes, which are found at high
frequency in various types of cancers, have been linked to aberrant activation of stem cell-
related pathways [19–21].
Probably the most compelling evidence supporting a key role of chromatin in the acquisition of
uncontrolled self-renewal comes from studies in glioblastoma (GBM), a highly aggressive form
of brain cancer characterized by an undifferentiated phenotype and a high frequency of CSCs.
Recent sequencing efforts have identiﬁed gain-of-function mutations in genes encoding
histone H3 in about one third of pediatric GBMs. The gene mainly affected is H3F3A, and
a K27M substitution is the most common alteration [22,23]. The primary mechanism leading to
oncogenesis induced by the K27M mutation is inhibition of the Polycomb repressive complex 2
(PRC2), which results in genome-wide reduction in the repressive histone H3 trimethylated
lysine 27 (H3K27me3) mark [24] and re-establishment of an earlier developmental program in
neural precursor cells and consequent acquisition of oncogenic self-renewal ability [25]. The
identiﬁcation of a histone protein as a key driver in GBM has particularly important implicationsTrends in Cancer, May 2017, Vol. 3, No. 5 373
because it demonstrates a direct and major role of chromatin in the emergence of CSCs.
Interestingly, H3.3 mutations are only found in pediatric GBM, suggesting a different mecha-
nism of CSC formation in adult patients. Nevertheless, chromatin dysregulation is likely to play a
crucial role in adult GBM as well, considering that approximately half of adult GBMs harbor
mutations in at least one chromatin modiﬁer [26].
DNA Methylation-Related Drivers Inducing CSC Formation
Proteins involved in the establishment and maintenance of DNA methylation have also been
identiﬁed as drivers of CSC formation. The methylation status of CpG dinucleotides depends on
the action of DNA methyltransferases (DNMT1, DNMT3A, and DNMT3B), which apply the
methyl-group to cytosines, and methylcytosine dioxygenases (TET1 and TET2), which convert
5-methylcytosine to 5-hydroxymethylcytosine and initiate a demethylation process. DNMT3A is
the DNMT most commonly affected by DNA lesions, being mutated in 25% of AML patients
[27]. Most DNMT3A mutations appear to inhibit the enzyme activity and lead to expansion of
pre-LSCs, although the exact mechanism underlying this process is not fully understood and
both DNA methylation-dependent and -independent mechanisms have been described [28–
32]. Interesting, loss-of-function mutations in TET proteins, which antagonize the function of
DNMTs, and mutations in IDH proteins, which indirectly affect DNA methylation patterns, also
lead to the expansion of pre-LSCs, suggesting that disruption of DNA methylation via multiple
mechanisms can have similar consequences [27]. The role of aberrant DNA-methylation
patterns in the early stages of tumorigenesis is not limited to leukemia, and mutations in
DNMTs and IDHs have been also observed in solid tumors [33,34].
The studies discussed above are only selected examples illustrating how mutations in epige-
netic regulators crucially contribute to the formation of the founder CSC in various malignan-
cies. As a group, epigenetic regulators are among the most commonly mutated proteins, both
in individual cancer types and in pan-cancer cohorts [35,36]. Some of these genetic lesions
lead to oncogenic gain of function such as those generating MLL fusions, while others damage
proteins that act as tumor suppressors. Regardless of the type of mutations, a common
consequence of such alterations is a global reorganization of the epigenome and consequent
disruption of differentiation programs. Mutations can occur in normal stem cells, where they
mainly disrupt the balance between self-renewal and differentiation, or in committed cells,
where they induce a reprogramming process conferring de novo self-renewal capacity. In both
cases, epigenetic constraints imposed during development to keep cellular plasticity under
control are disrupted, and cells transform, losing their normal cellular identity (Figure 1).
Epigenetic Mechanisms Affecting CSC Maintenance
The acquisition of uncontrolled self-renewal is only the ﬁrst step in the development of a cancer.
Transformed cells need to maintain their ability to self-renew while the cancer grows, a task that
is evidently not trivial considering that CSCs are often only a small subset of the cancer cell
population and that most cells lose self-renewal capacity over time.
Transcriptional Intratumoral Heterogeneity
The presence of at least two functionally distinct subsets of cells (tumorigenic self-renewing
CSCs, and non-tumorigenic differentiated cells) in many cancers has been the basic observa-
tion supporting the hierarchical model of cancer development over the past two decades.
Recent single-cell transcriptomic studies have extended our understanding of the gene
expression programs that shape tumor architecture and have conﬁrmed that aberrant differ-
entiation programs establish cellular hierarchies within individual cancers. In a pioneering study,
colon cancers were shown to contain multiple cell types with transcriptional proﬁles resembling
those of the cellular lineages making up the normal epithelium. Importantly, single cancer cells
could recapitulate the lineage diversity of the primary tumors in transplantation assays,374 Trends in Cancer, May 2017, Vol. 3, No. 5
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Figure 1. Oncogenic Reprogramming Induced by Mutated Epigenetic Regulators. Genetic alterations in chromatin-related proteins and factors involved in
the establishment and maintenance of DNA methylation lead to disruption of epigenetic regulation in either adult stem cells or committed cells, and promote neoplastic
transformation. The normal function of epigenetic mechanisms (left, in blue) and the consequences of epigenetic alterations induced by mutations (right, in red) are
indicated. Normal or altered chromatin in the cell nucleus is depicted in color or in grey, respectively. Empty and black circles represent unmethylated and methylated
CpGs, respectively. Chromatin image adapted from the webpage of the laboratory of S. Tang (www.personal.psu.edu/sxt30/projects_chromatinenzymes.html).
Abbreviation: CSC, cancer stem cell.demonstrating that multilineage differentiation represents a key source of intratumoral tran-
scriptional heterogeneity [37]. Similar studies in glioblastoma and oligodendroglioma have
conﬁrmed this ﬁnding, showing that brain tumors contain subpopulations of undifferentiated
cells characterized by stem cell and proliferation gene signatures, and subsets of cells that have
lost self-renewal potential through neural differentiation [38,39]. The approach used in these
studies is powerful because it allows reconstruction of cellular hierarchies from genome-wide
expression signatures in primary tumors, avoiding the caveats associated with xenograft
assays. However, one limitation of these studies is their descriptive nature, which cannot
assign causality to the identiﬁed gene signatures in the absence of functional validation.
The observation that IDH-induced oligodendrogliomas contain differentiated, non-self-renew-
ing cells underscores the diverse, and at times antithetic, role of epigenetic mechanisms in
cancer development. During tumorigenesis, mutations in IDH proteins drive CSC emergence
partly through alteration of DNA methylation proﬁles and epigenetic reprogramming of com-
mitted oligodendrocytes. However, during tumor growth, additional epigenetic changes occur
and establish developmental hierarchies that restrict the proliferative potential of some cells,
counteracting the effect of the initiating mutations (Figure 2).
Epigenetic Regulators That Inhibit Cancer Cell Self-Renewal and Establish Cellular
Hierarchies
What are the mechanisms that generate distinct epigenetic states within tumors and confer
distinct functional properties to CSCs and differentiated cells? Epigenetic regulators belonging
to two distinct groups have so far been identiﬁed: those that inhibit cancer cell self-renewal and
establish differentiation hierarchies, and those that are hijacked by CSCs to avoid differentiation
and sustain their phenotype (Table 1). Within the ﬁrst group, the linker histone H1.0 plays an
important role in restricting cancer cells long-term proliferative potential and determines
functionally distinct subsets of cells within individual tumors [40]. In numerous cancer types,
H1.0 levels are highly heterogeneous, with low levels in cells expressing CSC markers and high
levels in differentiated cells. Functional characterization of the impact of H1.0 expression on
cancer cells revealed that only cells able to stably repress H1.0 preserve a chromatin conﬁgu-
ration compatible with self-renewal capacity. Re-expression of H1.0 in subsets of cells during
tumor growth induces genome-wide silencing of oncogenic and self-renewal genes, and
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Figure 2. Epigenetic Mechanisms Integrate Cell-Intrinsic and Cell-Extrinsic Changes Affecting Cancer Cells and Generate Functional Intratumoral
Heterogeneity. Schematic depiction of the distinct layers of alterations that affect cells during cancer development via epigenetic mechanisms. Initiating mutations
(pink dash inside the nuclei) affect the cell epigenome (cylinders inside the cell nuclei) either directly, when mutations hit epigenetic regulators, or indirectly, when
mutations in other drivers trigger gene expression changes mediated by chromatin remodeling and DNA methylation [100]. In either case, epigenetic reprogramming
translates mutations into malignant phenotypes and promotes the acquisition of uncontrolled self-renewal. Secondary mutations occurring during tumor growth (red
and black dashes) and signals from tumor microenvironment (pink, red, and black dots outside cells) induce further changes in the epigenome of the cells, either
enhancing (red) or inhibiting (black) cancer cell self-renewal in a subclone- and context-dependent manner. The phenotype of each cell within a tumor is the result of all
these alterations, which collectively shape the epigenome of the cell and determine which cells drive cancer growth. In the combined layers, the cell with a pink nucleus
and a thin arrow represents a cell that has maintained the self-renewal ability conferred by the initiating events. Cells with red nuclei and thick arrows represent cells with
enhanced self-renewal ability due to either favorable secondary mutations (cell on the right) or signaling (cell on the left). Cells with grey nuclei represent cells that have
lost self-renewal ability due to either deleterious secondary mutations or signaling.H1.0 levels can maintain CSC properties. As discussed above for mutations in H3.3, the
observation that an integral component of chromatin acts as an important regulator of cancer
cell differentiation states highlights the important role of epigenetics in specifying tumor
organization and affecting tumor maintenance. Another example supporting this concept376 Trends in Cancer, May 2017, Vol. 3, No. 5
Table 1. Non-Mutated Epigenetic Regulators Affecting Cancer Cell Self-Renewal and Plasticitya
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Table 1. (continued)




MLL5 Glioblastoma KD and OE studies with
human primary GBM cultures
in vitro and in graft models
Differentiation N/A N/A [54]
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aKD, knockdown; KO, knockout, N/A, not available; OE, overexpression. The registered clinical trial identiﬁer (NCT) is indicated (www.clinicaltrials.gov).comes from MLL-driven AML, in which high levels of the histone demethylase KDM5B revert
the histone modiﬁcation patterns and gene expression programs established by MLL during
leukemogenesis, thereby extinguishing LCS potential [41]. Similarly, in glioma the histone
methyltransferase G9a and the related global increase in H3K9me2 inhibit self-renewal of
CSCs in vitro [42]. Although the presence of cellular hierarchies is recognized in many cancers,
our knowledge of how they are established and how cancer cells lose self-renewal capacity
during tumor growth is still rudimental. A comprehensive identiﬁcation of the molecular players
that drive cancer cell differentiation is central to understanding, and possibly exploiting, the
mechanisms that naturally inhibit tumor maintenance and deprive cancer cells of their malignant
properties.
Epigenetic Regulators That Sustain Cancer Cell Self-Renewal
Although many cancer cells succumb to differentiation during tumor growth, CSCs evade this
process and preserve their self-renewal capacity acquired during transformation. Not surpris-
ingly, considering the importance of epigenetic regulators in normal stem cell maintenance,
many chromatin-related proteins and DNA-methylating enzymes are essential to maintaining
the CSC state. Remarkably, most of the proteins implicated in CSC maintenance are typically
not mutated but are co-opted in their wild-type state by CSCs to avoid differentiation and
sustain their malignant properties. Prominent examples of hijacked proteins are Polycomb
complex proteins. The PRC2 catalytic subunit EZH2 has a tumor-promoting role in many
malignancies, and inhibition of its activity or genetically induced loss of the protein strongly
impairs tumor growth [43–50]. Several molecular mechanisms, not always dependent on EZH2
methyltransferase activity, have been shown to underlie the role of EZH2 in cancer, including
repression of tumor suppressors [43–50], activation of oncogenic NOTCH signaling [47],
stabilization of b-catenin [48], and inhibition of DNA damage repair and consequent induction
of secondary mutations [50]. Regardless of the speciﬁc mechanism, the commonality in all
these cases is that cells become dependent on EZH2 to preserve their self-renewal potential, as
a consequence of the cellular changes induced by transformation and other alterations
occurring during tumor growth. Other PcG proteins such as a non-canonical PRC1.1 complex
in AML [51] and BMI1 in glioma [52] exert similar functions. Histone modiﬁers in general have
often been reported as positive regulators of CSC self-renewal (Table 1) [53–64]. Furthermore,
the chromatin-remodeling complex SWI/SNF sustains high levels of c-MYC by regulating
enhancer function and is required for maintenance of self-renewing LSCs in MLL-driven
leukemia [65]. Interestingly, in many cases, functional dependency on chromatin regulators
is observed in neoplasms initiated by mutations targeting other epigenetic regulators,Trends in Cancer, May 2017, Vol. 3, No. 5 379
highlighting the complex role of epigenetics in cancer and the existence of synthetic lethality
interactions that could be exploited for therapeutic purposes [44–46,53,57,64].
Epigenetic Modulation of the CSC State
A key feature of epigenetic mechanisms is their inherent reversibility. Thus, the dependence of
CSCs on epigenetic regulators offers an opportunity to target their self-renewal capacity. The
chromatin ‘reader’ BRD4 best illustrates this concept [66]. BRD4 belongs to the BET family of
chromatin readers which bind to acetylated promoters and enhancers and sustain transcription
of the corresponding genes. Many key oncogenes, the most notable example being c-MYC,
are among BRD4 targets, and pharmacological inhibition of BRD4 binding to their regulatory
regions strongly reduces their expression levels and inhibits the growth of various cancer types
[67–69]. Pioneering studies in MLL-driven ALL demonstrated that BRD4 inhibitors (BETis)
effectively target CSCs [67,68], a ﬁnding conﬁrmed in other cancer types [70,71]. The striking
preclinical results obtained with BETis, reinforced by early clinical evidence [72], highlight the
potential of targeting epigenetic mechanisms, showing how c-MYC, a classical untargetable
oncoprotein key to many CSCs, can effectively be eliminated through interference with its
upstream regulator. The case of BRD4 is remarkable in that it appears to affect the mainte-
nance of a wide range of cancers. However, several successful preclinical studies focused on
inhibition of other chromatin-related proteins in speciﬁc cancer types have conﬁrmed the
therapeutic value of targeting epigenetic regulators and have laid the foundation for ongoing
clinical trials [57,60,73] (Table 1).
As with any therapeutic strategy, epigenetic modulation of CSCs faces challenges. Early
concerns regarding targeting wild-type proteins that exert pleiotropic functions in normal cells
have been mitigated by the observation that many tested inhibitors are not associated with
major toxicity, suggesting that cancer cells exhibit a speciﬁc epigenetic vulnerability [74].
However, there is evidence that BETis, for example, may have deleterious effects [75,76]
and treatment regimens will need to be carefully adjusted to avoid long-term side-effects.
Furthermore, while the development of resistance is theoretically less likely when targeting
downstream epigenetic regulators compared to treatments interfering with upstream cellular
components – extracellular or cytoplasmic proteins that can be easily bypassed using parallel
pathways – resistance also can emerge when targeting nuclear components. At least two
distinct mechanisms of acquired resistance to BETis have been identiﬁed in AML and breast
cancer [77,78], although characterization of the resistance mechanisms has suggested com-
bination strategies that may enhance the clinical utility of BRD4 inhibition. Finally, despite
successful preclinical studies, consistent efﬁcacy of epigenetic drugs, such as HDAC inhibitors
and DNA methylation inhibitors, has not always been observed in patients, especially in solid
tumors [79,80].
Cell-Extrinsic Mechanisms Affecting CSC Function and Maintenance
through Epigenetics
A key question related to epigenetic regulation of the CSC state is: what determines epigenetic
heterogeneity within tumors? For example, why do some cells express high levels of histone
H1.0 and consequently differentiate, and others instead maintain low H1.0 levels and thus self-
renewal capacity [40]? Similarly, why are HOX oncogenes methylated in their promoter regions
in particular AML cells and not in others [81]? Various pieces of evidence indicate that genetic
differences alone cannot account for the observed degree of diversity, and that cell-extrinsic
mechanisms play an important role. Tumors comprise a diverse ecosystem of cancer cells
surrounded by vasculature, cancer-associated ﬁbroblasts, and inﬁltrating immune cells. This
microcosm provides numerous cell-to-cell signals that modulate gene expression programs in
cancer cells independently of their genetic background and, as a consequence, affect the
number, phenotype, and function of CSCs [82].380 Trends in Cancer, May 2017, Vol. 3, No. 5
Interplay between Extracellular Signaling and Epigenetics in Generating Intratumoral
Functional Heterogeneity
Variations in oxygen and nutrient concentrations are a likely source of phenotypic variation
within tumors, and histone modiﬁers have been reported to act as sensors of hypoxia [83] or are
linked to metabolism [84]. Similarly, DNA methylation patterns are affected by changes in the
environment [85]. Thus, cells exposed to distinct conditions in their local environment may
respond by modifying their epigenome. Furthermore, classic cell-to-cell signaling pathways,
such as WNT, TGF-b, SHH, and NOTCH, which tightly regulate self-renewal and differentiation
during embryonic development and adult tissue homeostasis, affect CSC self-renewal either
positively or negatively [86]. In physiological conditions, the heritable switch from division to
differentiation induced or prevented by these pathways is determined by changes in chromatin
and DNA methylation [87]. Although the downstream effectors of aberrant developmental
pathways in cancer are largely unknown, it stands to reason that epigenetic factors are likely to
be crucial mediators that translate extracellular signaling into differential phenotypes withinKey Figure
The Complex Role of Epigenetic Mechanisms in Cancer
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Figure 3. The diagram summarizes mechanisms that affect cellular plasticity in cancer through changes in chromatin and
DNA methylation. Mechanisms operating during carcinogenesis unleash cellular plasticity. During tumor growth, cellular
plasticity is exploited by cancer cells (hijacking) and is further modulated either positively, to favor adaptation of cells and
cancer growth (enhancing), or negatively (restricting). Blue, red/purple, and grey cells represent normal cells, self-
renewing, and differentiated cancer cells, respectively. Double arrows indicate reversible transitions between cell states.
Mechanisms involving indirect reprogramming of the epigenome by oncogenic hits or environmental cues are not
discussed in this review because they have been described elsewhere [100,101]. Abbreviation: CSC, cancer stem cell.
Trends in Cancer, May 2017, Vol. 3, No. 5 381
cancers. In line with this view, functional interactions between TGF-b and two histone modiﬁers,
PRMT5 [88] and G9a [89], modulate cancer cell phenotypes in various types of carcinoma
through changes in histone methylation. Moreover, the transcriptional regulator CDK9 has
been found to act as a downstream effector of the NOTCH pathway to sustain GBM stem cells
[90]. In addition, cAMP, a second messenger involved in transduction of various extracellular
signals, promotes breast CSC differentiation via the histone demethylase PHF2 [91]. Because
chromatin-based mechanisms represent the last level of signal transduction cascades, and
several ‘epigenetic’ drugs have already been developed, ﬁnding novel mechanisms where
chromatin-related factors mediate CSC-sustaining signaling pathway activity could have
important therapeutic implications (Figure 3, Key Figure). As an additional layer of complexity,
distinct epigenetic states can in turn determine the response to microenvironment signaling, as
exempliﬁed by breast and glioma CSCs in which the tumor-suppressive or tumor-promoting
effect of paracrine TGF-b signaling is determined by the DNA methylation status of SMAD
target genes [92,93]. Thus, the interplay between signaling and the epigenome has emerged as
a crucial force that shapes tumor architecture, and future characterization of these complex
interactions will certainly provide invaluable insights into CSC biology (Figure 2).
Reversible Epigenetic States and Cancer Cell Plasticity
A major difference between normal cellular hierarchies and cancer is that, although cell fate
decisions triggered by environmental cues are generally stable and heritable in normal cells,
cancer cells maintain an intrinsic plasticity that allows them to easily change their phenotype in
response to new signals and possibly switch between cellular states. Evidence exists in some
cancers that differentiated cells can reacquire self-renewal ability and revert to a CSC state
(Figure 3). This occurs, for example, in basal carcinomas of the breast, in which TGF-b
stimulation induces conversion of non-tumorigenic CD44lo cells to CD44hi CSCs. Importantly,
this cellular plasticity appears to be dependent on the chromatin status of the ZEB1 promoter
because a poised, bivalent conﬁguration allows reversion to CD44hi CSCs upon stimulation,
while the presence of repressive marks renders CD44lo cells insensitive to TGF-b [94]. Another
example highlighting how chromatin states can inﬂuence cancer cell plasticity comes from
melanoma, a type of cancer that does not appear to develop in a hierarchical manner [95]. Even
in the absence of ‘classical' CSCs, Roesch et al. identiﬁed a subpopulation of cells that is
required for continuous tumor growth and is marked by the expression of the histone deme-
thylase JARID1B. However, instead of being a stable subpopulation, JARID1B+ cells are a
dynamic subset whose composition changes over time as cells gain and lose JARID1B
expression, and transiently acquire stemness properties depending on the tumor context
[96]. These observations support a model of transient stemness, sustained by dynamic
epigenetic states, in which at any given time a self-renewing but changing subpopulation of
cells exists among the bulk of tumor cells. An important implication of these ﬁndings, which can
be extended to classical hierarchically organized tumors, is that the local tumor context appears
to be key in determining, through epigenetics, which cells within a tumor can act as tumor-
maintaining CSCs, arguing against a deterministic model of CSC identity.
Adaptive Chromatin Remodeling and Resistance to Therapy
Despite signiﬁcant progress in the development of effective therapies against numerous cancer
types, therapeutic resistance is still relatively common. CSCs are the likely source of resistant
cells responsible for disease relapse because cells deprived of self-renewing potential are
unable to reconstitute the cancer even if they survive treatment. While drug resistance primarily
has a genetic basis, chromatin-related mechanisms have emerged as additional players in this
context that are exploited by cancer cells to enhance their plasticity and adaptability (Figure 3).
A paradigm of epigenetically driven resistance has recently been provided by Sharma et al. who
reported the existence of a reversible drug-tolerant state in non-small cell lung cancer (NSCLC)-
derived cell lines, and which can survive exposure to lethal concentrations of EGFR tyrosine382 Trends in Cancer, May 2017, Vol. 3, No. 5
Outstanding Questions
What is the role of cellular hierarchies in
cancer? Do differentiated cells help
CSCs in any way, possibly through
paracrine signaling – or is differentia-
tion simply one of many anticancer
safeguard mechanisms that cells must
evade to establish a ‘successful’ can-
cer? If the latter, can epigenetic mech-
anisms naturally driving loss of self-
renewal be exploited for therapeutic
purposes?
What are the upstream mechanisms
that establish epigenetic heterogeneity
within individual tumors? What deter-
mines whether the different epigenetic
states are stable or whether a dynamic
equilibrium between self-renewing and
non-self-renewing (or drug-sensitive
and drug-tolerant) cells is established?
Can cancer cell plasticity be modu-
lated to reduce resistance to treat-
ment? How prevalent are epigenetic
mechanisms in the development of
therapeutic resistance?
Why do cancer cells, including CSCs,
show speciﬁc sensitivity to epigenetic
drugs that target wild-type proteins
expressed in normal cells as well?
Could epigenetic drugs be generally
useful as agents to be administered
in combination therapies?kinase inhibitors. This drug-tolerant state does not involve drug efﬂux and is instead associated
with an altered chromatin state and requires the histone demethylase KDM5A/JARID1A and
IGF-1R signaling [97]. Similarly, upon treatment with targeted kinase inhibitors, GBM CSCs can
reversibly transition to a slow-cycling persistent state in which primitive developmental pro-
grams are upregulated. The parallels with NSCLC extend to the dependence on a speciﬁc
signaling pathway, NOTCH, and a histone demethylase, KDM6A/B [98]. In both cases it is
hypothesized that this reversible chromatin state allows cancer cells to survive the initial lethal
stress before further, more permanent, resistance mechanisms can evolve. As an additional
example, in NOTCH1-driven T cell ALL, clinical trials using g-secretase inhibitors (GSI) have
shown limited efﬁcacy owing to the presence of a reversible subpopulation of GSI-tolerant cells
characterized by BRD4-dependent transcriptional programs. Notably, combined treatment of
patient-derived xenografts with NOTCH and BRD4 inhibitors showed greater efﬁcacy than
individual treatments [99]. Overall, these studies reveal that chromatin-related mechanisms
frequently characterize therapeutic resistant cancer cell subpopulations, and support the use of
epigenetic-targeting drugs in combination therapies as a means to overcome drug resistance
(Figure 3).
Concluding Remarks
Epigenetic alterations affecting chromatin and DNA methylation patterns are universal features
of cancer. Historically, it has been difﬁcult to distinguish whether these changes play a
functional role in the disease or are a bystander phenomenon that merely reﬂects alterations
in cell behavior. However, studies over the past 5–10 years have crystallized the importance of
epigenetic mechanisms at various stages of cancer development and have uncovered unprec-
edented therapeutic opportunities (Figure 3). The realization that genes involved in epigenetic
regulation are among the most commonly mutated gene families has profound implications for
understanding the mechanistic basis of carcinogenesis, and these studies have revealed that
interference with differentiation programs is a major mechanism leading to CSC emergence.
Complementary to cancer genomics studies, the identiﬁcation of epigenetic regulators hijacked
by CSCs to sustain their phenotypes, and the functional characterization of cell-intrinsic
mechanisms that establish and maintain cellular hierarchies within cancers, have demonstrated
the crucial role of epigenetics in tumor maintenance and progression. Given the reversible
nature of epigenetic mechanisms, these ﬁndings have enormous therapeutic potential
(Figure 3). The impressive preclinical results obtained with BET inhibitors provide a paradigm
illustrating the power of epigenetic therapy. It is highly likely that additional proteins may exert
similarly important, and possibly widespread, roles in tumor maintenance. For instance, very
little is known about the downstream effectors that mediate CSC-sustaining cell-to-cell sig-
naling. The challenge in identifying such proteins is the absence of mutations and, often, of
transcriptional alterations, which make them ‘invisible’ to unbiased genome-wide analysis.
Functional screening leveraging novel technologies such as CRISPR/Cas9 genome editing
may aid the identiﬁcation of novel therapeutic targets, especially if coupled with CSC-relevant
assays.
An alternative strategy to target CSCs, which has been explored only in part, is induction of their
differentiation by enhancing the natural process that occurs in vivo. The presence of cellular
hierarchies in cancer clearly indicates that mechanisms inhibiting cell self-renewal ability exist,
and can efﬁciently deprive cells of their malignant properties. Differentiation therapies that
‘exaggerate’ such mechanisms and restrict cellular plasticity may prove useful to exhaust CSCs
and thus halt tumor maintenance, and also to impair cancer cell adaptability (Figure 3). A
prerequisite to achieve this is a comprehensive understanding of the driving forces that shape
tumor architecture, and further research in this direction is essential (see Outstanding
Questions).Trends in Cancer, May 2017, Vol. 3, No. 5 383
Considering the diverse role of epigenetics in cancer, and the possible interference with normal
homeostasis, epigenetic modulation of CSCs clearly still faces many challenges, but at the
same time offers unprecedented opportunities to hit the beating heart of the disease.
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